8-K: Protagonist Therapeutics Stockholders Re-Elect Directors, Approve Executive Compensation and Auditor at 2025 Annual Meeting

Protagonist Therapeutics, Inc. announced the successful approval of all three proposals at its 2025 Annual Meeting of Stockholders, including the re-election of two Class III directors, the advisory approval of executive compensation, and the ratification of its independent auditor.

Summary

• Protagonist Therapeutics, Inc. held its 2025 Annual Meeting of Stockholders on June 20, 2025.
• As of the record date, April 23, 2025, there were 61,957,230 shares of common stock entitled to vote.
• Stockholders re-elected Harold E. Selick, Ph.D. and Bryan Giraudo as Class III directors to serve until the 2028 Annual Meeting.
• Harold E. Selick, Ph.D. received 44,822,907 votes For and 9,210,036 Withheld.
• Bryan Giraudo received 42,499,790 votes For and 11,533,153 Withheld.
• The non-binding, advisory proposal to approve the compensation of the company's named executive officers was approved with 50,844,517 votes For, 2,850,473 Against, and 337,953 Abstentions.
• The selection of Ernst & Young LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2025, was ratified with 55,480,739 votes For, 74,233 Against, and 396,488 Abstentions.

Sentiment

Score: 7

Explanation: The sentiment is positive as all proposals passed as expected, indicating stable corporate governance and shareholder alignment. There are no negative surprises or significant issues reported.

Positives

• All three proposals presented at the Annual Meeting were approved by the requisite votes, indicating strong stockholder support for the company's governance and management.
• The re-election of both director nominees ensures continuity in the board's Class III leadership.
• The approval of executive compensation on an advisory basis suggests stockholder alignment with the company's compensation practices.
• The ratification of Ernst & Young LLP as the independent auditor provides assurance of continued financial oversight.

Future Outlook

The document does not contain specific forward-looking statements or guidance regarding future financial performance or strategic initiatives beyond the routine governance matters.

Industry Context

This 8-K filing details the outcomes of a routine annual stockholder meeting, which is a standard corporate governance event for publicly traded companies in the biotechnology and pharmaceutical industry. The approvals of director elections, executive compensation, and auditor ratification are typical agenda items for such meetings and reflect the company's adherence to standard corporate governance practices.

Comparison to Industry Standards

• The conduct of an annual meeting and the voting on director elections, executive compensation, and auditor ratification are standard corporate governance practices across the biotechnology and pharmaceutical industry, aligning with global benchmarks for public companies.
• The voting results, with all proposals passing, suggest a level of shareholder support comparable to well-governed companies in the sector, such as Amgen (AMGN) or Gilead Sciences (GILD), where routine governance proposals typically pass with strong majorities.

Management Changes

Corporate Governance

Stakeholder Impact

• Shareholders: The voting results confirm the re-election of directors and approval of key governance matters, providing clarity on the company's leadership and policies.
• Management: The advisory approval of executive compensation indicates shareholder confidence in the current compensation framework.
• Employees: No direct impact mentioned, but stable governance can contribute to a stable work environment.
• Auditors: Ernst & Young LLP's ratification ensures their continued role in auditing the company's financial statements.

Next Steps

• The newly elected Class III directors, Harold E. Selick, Ph.D. and Bryan Giraudo, will hold office until the 2028 Annual Meeting of Stockholders.
• Ernst & Young LLP will continue as the independent registered public accounting firm for the fiscal year ending December 31, 2025.

Key Dates

Keywords

Protagonist Therapeutics, PTGX, Annual Meeting, Stockholders Meeting, Director Election, Executive Compensation, Auditor Ratification, Corporate Governance, SEC Filing, 8-K